78022-19-2

Upstream product

• 34040-64-7 p-methyloxycarbonylbenzyl chloride 
• 121-45-9 phosphorous acid trimethyl ester 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 

Downstream Products

• 132102-21-7 methyl (E)-4-<2-(2,2,4,4-tetramethylthiochroman-6-yl)-1-propenyl>benzoate 
• 132125-40-7 methyl (E)-4-<2-(trifluoromethyl)-2-(4,4-dimethylchroman-6-yl)ethenyl>benzoate 
• 132102-24-0 methyl (E)-4-<2-(trifluoromethyl)-2-(4,4-dimethylthiochroman-6-yl)ethenyl>benzoate 
• 121638-19-5 methyl (E)-4-<2-(trifluoromethyl)-2-(2,2,4,4-tetramethylthiochroman-6-yl)ethenyl>benzoate 
• 136423-91-1 (E)-methyl 4-<2-<3-(2,2-dimethoxyethoxy)-2-pyridinyl>ethenyl>-benzoate 
• 110983-40-9 4-[(E)-2-(2-Hydroxy-phenyl)-vinyl]-benzoic acid methyl ester 
• 809275-25-0 3-(4-methoxycarbonyl-benzylidene)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester 
• 519179-43-2 7-{1-[2-(4-methoxycarbonyl-phenyl)-vinyl]-hexyl}-4,4-dimethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 1305348-89-3 methyl 4-[(1E)-4-(adamant-1-yl)but-1-en-1-yl]benzoate 
• 798562-50-2 C₃₄H₄₀N₂O₄ 
• 798562-49-9 4-[[4-[(diethylamino)carbonyl]phenyl](2-hydroxyphenyl)methylene]-1-piperidinecarboxylic acid tert butyl ester 

Relevant academic research and scientific papers

Tuned-affinity bivalent ligands for the characterization of opioid receptor heteromers

Opioid receptors, including the μ- and δ-opioid receptors (MOR and DOR), are important targets for the treatment of pain. Although there is mounting evidence that these receptors form heteromers, the functional role of the MOR/DOR heteromer remains unresolved. We have designed and synthesized bivalent ligands as tools to elucidate the functional role of the MOR/DOR heteromer. Our ligands (L2 and L4) are comprised of a compound with low affinity at the DOR tethered to a compound with high affinity at the MOR, with the goal of producing ligands with "tuned affinity" at MOR/DOR heteromers as compared to DOR homomers. Here, we show that both L2 and L4 demonstrate enhanced affinity at MOR/DOR heteromers as compared to DOR homomers, thereby providing unique pharmacological tools to dissect the role of the MOR/DOR heteromer in pain.

DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of formula: wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in p

DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of Formula: wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in p

DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of general formula: wherein R1, R2, R3, R4, and R5 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prep

PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS

Compounds of general formula: wherein R1, R2 and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

4-{`3-(SULFONYLAMINO) PHENYL! `1-(CYCLYMETHYL) PIPERIDIN-4-YLIDENE! METHYL} BENAZMIDE DERIVATIVES AS DELTA OPIOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN, ANXIETY AND FUNCTIONAL GASTROINTESTINAL DISORDER

Compounds of general formula: (I) wherein R1,R2, R3, R4 and R5 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds

DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, m and n are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in pa

DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of general formula: Formula (I) wherein R1, R2, R3 and A are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are u

DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPIOD RECEPTOR AGONISTS

Compounds of general formula: (Formula (I)) wherein R1, R2, R3, R4 and R5 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compo

DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of general formula: Formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.